Flash irradiation delivered in a IBA ProteusONE proton therapy treatment room

Huge Two-Day Clean Sweep Auction July 24-25th. Click Here to Bid!

Aktueller Standort:
> This Story

Forward Printable StoryPrint Comment




Rad Oncology Homepage

Swiss Medical Network advances cancer care in Switzerland with multi-system agreement for Accuray radiation therapy systems

MVZ Prof. Dr. Uhlenbrock and Partner select C-RAD’s SIGRT solution

Cyclotron rigging completed in Guangzhou, Guangdong Province, China

Radsource completes 16 ProtonPACS installations in Q2: 2019

RaySearch and Vision RT announce strategic partnership

Sun Nuclear to showcase key quality management advances at AAPM 2019

Elekta to demonstrate leadership in precision radiation medicine at AAPM with launch of new QA portfolio

Johns Hopkins Medicine researchers identify health conditions likely to be misdiagnosed

Are doctors treating more thyroid cancer patients than necessary?

C-RAD to focus its sales resources on its core business going forward

Flash irradiation delivered in a IBA ProteusONE proton therapy treatment room

Press releases may be edited for formatting or style
Louvain-la-Neuve, Belgium, 11 June 2019 – IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions, is pleased to announce the first Flash irradiation in an IBA Proteus®ONE compact gantry treatment room at the Rutherford Cancer Centre Thames Valley in Reading, United Kingdom, on June 8, 2019. This represents another major milestone for IBA and its medical and research partners in their work to lead the development of Flash irradiation.

Flash therapy has the potential to dramatically change the landscape of radiotherapy and patient cancer care, making it more effective, cheaper and therefore more accessible. Flash irradiation is a fast and powerful treatment that delivers a high dose of radiation at an ultra-high dose rate. This novel technique could potentially shorten treatment from 6-8 weeks to 1-2 weeks and has the potential to reduce side effects for patients.

Story Continues Below Advertisement


Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.

IBA has always led research in proton therapy and has filed its first patent related to Flash in 2010. This early development work enables IBA today to deliver Flash irradiations on both its current single and multi-room proton therapy platforms in clinical environment. In March, IBA successfully performed a Flash irriadiation in its Proteus®PLUS clinical treatment room at the University Medical Center of Groningen. With this latest milestone , IBA demonstrates that its full range of Proteus® equipment is Flash-capable.

As the world's leader in protontherapy, IBA will share the latest developments on Motion Management, Arc Therapy and Flash during its symposium at the PTCOG Congress in Manchester on Friday June 14.

Olivier Legrain, Chief Executive Officer, IBA: "We are delighted about the results obtained at the Rutherford Cancer Center in Reading, demonstrating IBA's technology leadership in Flash therapy research, now for both our multiroom and compact proton therapy solutions. Building on our unique and open culture of collaborative innovation, IBA continues its commitment to further develop Flash therapy. To achieve this we will continue to partner with the most experienced user community to study the radiobiology of proton Flash irradiation and help our clinical partners by accelerating access to the latest innovations in proton therapy."

Prof. Karol Sikora, Chief Medical Officer at Proton Partners International: "We are pleased to be working closely at developing futuristic therapies with IBA - the world's leading proton equipment manufacturer. We are delighted that our patients will be amongst the first to gain from the convenience of short course radiotherapy and look forward to pioneering the latest developments in this exciting area."
  Pages: 1 - 2 >>

Rad Oncology Homepage

You Must Be Logged In To Post A Comment